CTRI/2021/07/035309已完成1 期
A randomised Phase-I safety and tolerability study of two dosing regimens of Quercetin bar inhealthy healthcare workers in a tertiary care hospital
Director Defence Institute of Physiology and Allied Sciences0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Ã¢â?¬Â¢Subject is a healthy male or female adult, aged 18 to 65 years on the day of enrolment
- •Ã¢â?¬Â¢Subject weighs at least 45 kg
- •Ã¢â?¬Â¢Subject willingness to participate in the study with signed Informed Consent Form
排除标准
- •Ã¢â?¬Â¢Subject has any clinically significant illness which is likely to impact the safety of patient or may affect the results of the study
- •Ã¢â?¬Â¢Subject has a known hypersensitivity or allergy to quercetin
- •Ã¢â?¬Â¢Study subject is participating in another drug trial
- •Ã¢â?¬Â¢Study subject is female and is pregnant or may get pregnant during the study period
- •Ã¢â?¬Â¢Study subject unwilling to sign informed consent
- •Ã¢â?¬Â¢Study subject is unlikely to complete the study
研究者
相似试验
已完成
不适用
Safety and efficacy of AKP-11 for atopic dermatitis.Skin - Dermatological conditionsAtopic DermatitisACTRN12616000294459Akaal Pharma PTY LTD21
已完成
1 期
A Phase 1 study to assess the safety, tolerability, and immunogenicity of VN-0200 after intramuscular injection in Japanese healthy adults and elderly subjectsPrevention of respiratory syncytial virusJPRN-jRCT2031210069Inoguchi Akihiro48
已完成
1 期
Safety and pharmacokinetics study in healthy Japanese volunteersJPRN-jRCT2051210087Owada Yasuko48
已完成
不适用
Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics and pharmacodynamics of monoclonal antibody TB31F in healthy malaria-naïve adults in the NetherlandsmalariaNL-OMON50099Radboud Universitair Medisch Centrum25
已完成
1 期
Safety, tolerability and pharmacokinetics study of WCK 2349 (in single doses) in healthy male volunteer.CTRI/2009/091/000377Wockhardt Ltd84